Cargando…
Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies
Autores principales: | Al Hadidi, Samer, Kamble, Rammurti T., Carrum, George, Heslop, Helen E., Ramos, Carlos Almeida |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759126/ https://www.ncbi.nlm.nih.gov/pubmed/34461636 http://dx.doi.org/10.1182/bloodadvances.2021004190 |
Ejemplares similares
-
Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
por: Al Hadidi, Samer, et al.
Publicado: (2022) -
PB2463: PROTRACTED DIARRHEA FROM HIGH-DOSE MELPHALAN IN AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION: RESPONSE TO SHORT COURSE OF ORAL BUDESONIDE
por: Kamble, Rammurti, et al.
Publicado: (2023) -
Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018) -
Carbamazepine and Hematological Malignancies
por: Yavaşoğlu, İrfan, et al.
Publicado: (2013) -
Inonotosis in Patient with Hematologic Malignancy
por: Fernández-Cruz, Ana, et al.
Publicado: (2018)